Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03084965
Other study ID # D1690R00022
Secondary ID
Status Completed
Phase
First received
Last updated
Start date May 12, 2017
Est. completion date March 2, 2018

Study information

Verified date February 2019
Source AstraZeneca
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Retrospective Study of Patients With Type 2 Diabetes Mellitus on Dapagliflozin Therapy in Taiwan.


Recruitment information / eligibility

Status Completed
Enrollment 1987
Est. completion date March 2, 2018
Est. primary completion date March 2, 2018
Accepts healthy volunteers No
Gender All
Age group N/A to 99 Years
Eligibility Inclusion Criteria:

1. Outpatient equal to or more than 20 years of age.

2. T2DM patient initiated dapagliflozin after May 1st 2016 as a second line or third line oral anti-diabetic therapy, either as add-on or switching from one to another. Or initiating dapagliflozin as adjunctive therapy for T2DM subjects treated with insulin.

3. Completed follow-up of at least 6 months regardless of continuation on dapagliflozin therapy.

4. Will provide completed and signed written informed consents.

Exclusion Criteria:

1. Subjects with a history of SGLT2 inhibitor therapy other than dapagliflozin prior to Baseline.

2. Subjects with Type 1 diabetes.

3. Treatment with other investigational drugs concurrently during the retrospective data collection period.

Study Design


Locations

Country Name City State
Taiwan Research Site Changhua
Taiwan Research Site Chiayi
Taiwan Research Site Kaohsiung
Taiwan Research Site New Taipei
Taiwan Research Site Taichung
Taiwan Research Site Tainan
Taiwan Research Site Taipei
Taiwan Research Site Taoyuan

Sponsors (1)

Lead Sponsor Collaborator
AstraZeneca

Country where clinical trial is conducted

Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in HbA1c To assess the change from baseline (time to initiate dapagliflozin*) in HbA1c at 6 months 6 months
See also
  Status Clinical Trial Phase
Completed NCT01952535 - A Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of Oral HMS5552 in Healthy Volunteers Phase 1
Completed NCT01196728 - Single-centre, Randomised, Double-blind, Placebo-controlled, Four-way Crossover Clinical Study to Investigate Safety and Tolerability and Pharmacokinetics of Single Doses of CM3.1-AC100 in Patients With Type 2 Diabetes Phase 1
Terminated NCT00997152 - Efficacy and Safety Study of JTT-654 in Type 2 Diabetic Patients Phase 2
Completed NCT02592421 - SGLT2 Inhibition and Stimulation of Endogenous Glucose Production: Protocol 2 Phase 3
Completed NCT05544214 - Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD 371 in Healthy Subjects Phase 1
Completed NCT01969084 - The Effect of Linagliptin on Mitochondrial and Endothelial Function Phase 4
Terminated NCT01644201 - A Study Evaluating the Effects of a High Viscosity Non-starch Polysaccharide (PolyGlycopleX® - PGX®) on Glycemic Control, Cardiometabolic Risk Factors and Weight Loss in Overweight and Obese Type II Diabetics Phase 3
Completed NCT00995787 - Safety and Tolerability of AZD1656 in Type 2 Diabetes Mellitus (T2DM) Patients Treated With Metformin and Sulfonylurea Phase 1
Completed NCT01020123 - Evaluate Efficacy, Safety and Tolerability of AZD1656 as Add-on Treatment to Metformin in Type 2 Diabetes Mellitus (TD2M) Patients Phase 2
Completed NCT01505426 - A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Metformin in Asian Diabetes Patients Phase 3
Completed NCT01262586 - Vildagliptin Glycemic Profiles Assessment Using a Continuous Glucose Monitoring Device. Phase 3
Completed NCT00561171 - Phase IIa Study to Investigate the Efficacy and Safety of SPP635 in Diabetic and Hypertensive Patients With Albuminuria Phase 2
Active, not recruiting NCT03912363 - Intrapartum Glycemic Control With Insulin Infusion Versus Rotating Fluids N/A
Completed NCT01868646 - Clinical Trial of Efficacy and Safety of Subetta in the Combined Treatment of Patients With Type II Diabetes Mellitus Phase 4
Active, not recruiting NCT06386328 - A Clinical Trial to Evaluate the Food Effect of CKD-378 Phase 1
Terminated NCT02749435 - A Study to Evaluate the Effect of a Digital Disease Management Tool in Patients With Type 2 Diabetes Mellitus N/A
Completed NCT00894868 - Effect of Vildagliptin on Left Ventricular Function in Patients With Type 2 Diabetes and Congestive Heart Failure Phase 4
Recruiting NCT01165190 - Effect of Pioglitazone on Mitochondrial Function in Muscle and Adipose Tissue in Humans N/A
Completed NCT01255085 - Yellow Pea Protein and Fibre and Short Term Food Intake N/A
Completed NCT02156349 - A Study Evaluating the Efficacy and the Benefit of Integrated Personalized Diabetes Management (PDM) for Diabetic Patients. N/A